Clonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adh… Recalled: CGMP Deviations: use of an unapproved raw material
CGMP Deviations: use of an unapproved raw material
Searching CPSC consumer products, FDA food & drug enforcement reports, and USDA meat & poultry recalls — sorted newest first.
1,498 recalls found — page 40 of 63.
CGMP Deviations: use of an unapproved raw material
CGMP Deviations: use of an unapproved raw material
CGMP Deviations: use of an unapproved raw material
Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).
Subpotent Drug
Subpotent Drug
Subpotent Drug
Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.
Labelling: Illegible label
Failed Dissolution Specifications
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Lack of Assurance of Sterility
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
Failed tablet specifications.
FDA analysis revealed the presence of undeclared sildenafil
FDA analysis revealed the presence of undeclared sildenafil
Crystallization; identified as Buprenorphine free base
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
The recalled dressers are unstable if they are not anchored to the wall, posing tip-over and entrapment hazards that can result in risks of serious injuries or death to children. The dressers violate the mandatory standard as required by the STURDY Act.